Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule October 27, 2025
- Helicon Degraders Show a New Path in Prostate Cancer Therapy October 27, 2025
- UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer October 27, 2025
- Newsletter 43/2025 October 26, 2025
Phase 3 Trial: Xaluritamig (AMG 509) Plus Abiraterone in mCRPC
/in Clinical Trial, Metastatic, Phase 3/by MaxA large international Phase 3 clinical trial is evaluating a new treatment combination for men with metastatic castration-resistant prostate cancer (mCRPC) who have not yet undergone chemotherapy (in castration resistant settings, prior chemo is allowed). The study is testing xaluritamig (AMG 509) together with abiraterone acetate against the investigator’s choice of standard therapies (docetaxel, cabazitaxel, […]
UPDATE: Phase 1 Trial of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
/in Clinical Trial, Metastatic, Phase 1/by MaxA new Phase 1 clinical study, known as the ARTISAN trial, is evaluating an investigational lead-212 alpha radioligand therapy targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). We discussed AB001 in a previous article; the trial has now been approved, and its full details are available. The therapy combines a […]
Phase 1/2 Study: New Combination Therapy Combines Tulmimetostat (DZR123) and JSB462 (aka Luxdegalutamide aka ARV-766)
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxUPDATE: VIR-5500 Advances to Third Part of Phase 1 Study With Promising Early Results
/in Clinical Trial, Metastatic, Phase 1/by MaxNew Cancer Vaccine is Promising in Preclinical Research
/in Immunotherapy, Preclinical Research/by MaxAMPLITUDE: a Phase 3 Clinical Trial of Niraparib Combined with Abiraterone Acetate for HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxScientists Develop “Velcro” Cancer Treatment That Works Across Many Tumor Types
/in Immunotherapy, Preclinical Research/by MaxResearchers at the University of California, Irvine have developed an innovative cancer immunotherapy called GlyTR, a new class of treatment that uses a “velcro-like” mechanism to target sugar molecules abundantly present on cancer cells. Their findings were published in September 2025 in the prestigious journal Cell, marking a significant advancement in cancer immunotherapy. Traditional immunotherapies […]
New Study Uncovers Mechanism Behind T-Cell Exhaustion, Offering Hope for Prostate Cancer Immunotherapy
/in Immunotherapy, Preclinical Research/by MaxA study from The Ohio State University Comprehensive Cancer Center has illuminated a critical reason why cancer immunotherapy often fails: T-cell exhaustion driven by a novel stress pathway called TexPSR (proteotoxic stress response in T-cell exhaustion). Published in the prestigious journal Nature, this discovery reveals a proteotoxic shock in exhausted T cells caused by the […]